Section: Contact Information

First Name : **Jennifer**
Last Name : **Yeh**
Institution : **Harvard T.H. Chan School of Public Health**
Address 1 : **718 Huntington Avenue**
Address 2 :
City : **Boston**
State/Province/Region : **MA**
Country : **US**
Zip/Postal Code : **02115**
Phone Number : **617-432-2013**
Alternate Phone Number :
Email Address : **jyeh@hsph.harvard.edu**

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : **Yes**

The specific aims are clear and focused. : **Yes**

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title : **Developing a microsimulation model of the lifetime clinical course of childhood cancer**

Planned research population (eligibility criteria) :
CCSS individuals diagnosed between 1970 and 1999

Proposed specific aims :
Aim 1. Develop a microsimulation model of the lifetime clinical course of childhood cancer from diagnosis to death (from initial cancer, late effects or competing mortality).

Aim 2. Use the model to assess whether genetic testing at time of cancer diagnosis can improve risk stratification for treatment and follow-up care recommendations. Motivated by recently identified genetic variants associated with anthracycline-related cardiotoxicity, we will initially focus on CHF outcomes.

Will the project require non-CCSS funding to complete? : **Yes**

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :
NCI R01 application for the Feb 5, 2016 receipt date.

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : **No**

Biological samples : **No**

Medical record data : **No**
If yes to any of the above, please briefly describe. :

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy :
Chronic Disease : **Primary**
Psychology / Neuropsychology :
Genetics : **Secondary**
Cancer Control :
Epidemiology / Biostatistics : **Secondary**

Section: Outcomes or Correlative Factors

Late mortality : **Primary**
Second Malignancy :

Group: Health Behaviors

Tobacco :
Alcohol :
Physical activity :
Medical screening :
Other :
If other, please specify :

Group: Psychosocial

Insurance :
Marriage :
Education :
Employment :
Other :
If other, please specify :

Group: Medical Conditions

Hearing/Vision/Speech :
Hormonal systems :
Heart and vascular :
Respiratory :
Digestive :
Surgical procedures :
Brain and nervous system :
Other :
If other, please specify :

Group: Medications

Describe medications :

Group: Psychologic/Quality of Life

BSI-18 :
SF-36 : **Primary**
CCSS-NCQ :
PTS :
PTG :
Other :
If other, please specify :

Group: Other

Pregnancy and offspring :
Family history :
Chronic conditions (CTCAE v3) : **Primary**
Health status :

Group: Demographic

Age : **Correlative Factors**
Race : **Correlative Factors**
Sex : **Correlative Factors**
Other :
If other, please specify :

Group: Cancer treatment

Chemotherapy : **Correlative Factors**
Radiation therapy : **Correlative Factors**
Surgery : **Correlative Factors**

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center : **Yes**
Local institutional statistician : **Yes**
If local, please provide the name(s) and contact information of the statistician(s) to be involved. :
Zachary Ward (zward@hsph.harvard.edu) - Computer Programmer
Wendy Leisenring for CCSS statistical support
Will this project utilize CCSS biologic samples? : **No**
If yes, which of the following? :
If other, please explain :

Section: Other General Comments

Other General Comments :
We would like to request individual-level CCSS data to develop our proposed microsimulation model of the clinical course of childhood cancer.

CCSS data will be used to develop the late-effects component of the simulation model. Data for the initial cancer treatment and genetic testing pieces will be based on published clinical studies and other data sources (not CCSS data)